A total of 40 patients with EGFR-mutant NSCLC who had cancer progression on osimertinib were assigned to two groups, and received osimertinib in combination with either alisertib, an aurora kinase inhibitor, or sapanisertib, an mTOR inhibitor. This evidence concerns the gene EGFR and cancer.